You have 9 free searches left this month | for more free features.

Plexiform Neurofibroma (PN)

Showing 1 - 25 of 331

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Neurofibromatosis 1, Neurofibroma Plexiform Trial in Shanghai (Selumetinib)

Active, not recruiting
  • Neurofibromatosis 1
  • Neurofibroma Plexiform
  • Shanghai, China
  • +1 more
Jan 13, 2023

Neurofibromatosis 1 (NF1), Plexiform Neurofibromas (PN) Trial run by the NCI (Selumetinib)

Active, not recruiting
  • Neurofibromatosis 1 (NF1)
  • Plexiform Neurofibromas (PN)
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 31, 2023

Neurofibromatosis 1, Neurofibromatosis Type 1, NF1 Trial run by the National Cancer Institute (NCI) (AZD6244)

Active, not recruiting
  • Neurofibromatosis 1
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Aug 24, 2022

NF1, Neurofibromatosis, Plexiform Neurofibromas Trial in United States (Cabozantinib)

Active, not recruiting
  • NF1
  • +2 more
  • Los Angeles, California
  • +11 more
Jan 13, 2023

Malignant Peripheral Nerve Sheath Tumor Development in

Active, not recruiting
  • Neurofibromatosis 1
  • Peripheral Nerve Neoplasms, Malignant
    • Bethesda, Maryland
      National Cancer Institute (NCI)
    Jul 6, 2022

    Neurofibromatosis 1, Plexiform Neurofibroma (PN) Trial in Worldwide (Selumetinib, Placebo)

    Recruiting
    • Neurofibromatosis 1
    • Plexiform Neurofibroma (PN)
    • Gainesville, Florida
    • +40 more
    Jan 16, 2023

    Neurofibromatosis Type 1 Trial in Japan (Selumetinib)

    Active, not recruiting
    • Neurofibromatosis Type 1
    • Minato-ku, Japan
    • +3 more
    Jun 9, 2022

    Patients With PN NF1 Starting Selumetinib in Russia

    Recruiting
    • Neurofibroma
      • Moscow, Moskva, Russian Federation
      • +9 more
      Jun 4, 2023

      Neurofibromatosis 1, Plexiform Neurofibroma, NF1 Trial (Test group (Group A): FCN-159 8 mg, orally, once daily;, Control group

      Not yet recruiting
      • Neurofibromatosis 1
      • +2 more
      • Test group (Group A): FCN-159 8 mg, orally, once daily;
      • Control group (Group B): Placebo, orally, once daily;
      • (no location specified)
      Jun 16, 2023

      Disfigurement From Photographs of Neurofibromatosis Type 1

      Completed
      • Neurofibromatosis 1
        • Bethesda, Maryland
          National Institutes of Health Clinical Center
        Jan 20, 2023

        US Selumetinib Registry

        Not yet recruiting
        • Neurofibromatosis Type 1
        • Plexiform Neurofibromas
          • (no location specified)
          Jan 5, 2023

          Neurofibromatosis Type 1 Trial in Worldwide (Selumetinib granule formulation, Selumetinib capsule formulation)

          Recruiting
          • Neurofibromatosis Type 1
          • Selumetinib granule formulation
          • Selumetinib capsule formulation
          • Phoenix, Arizona
          • +17 more
          Aug 4, 2022

          Neurofibromatosis 1, Neurofibroma, Plexiform Trial run by the NCI (Medication Event Monitoring System (MEMS))

          Active, not recruiting
          • Neurofibromatosis 1
          • Neurofibroma, Plexiform
          • Medication Event Monitoring System (MEMS)
          • Bethesda, Maryland
            National Institutes of Health Clinical Center
          Feb 2, 2023

          Neurofibromatosis 1, Plexiform Neurofibromas Trial in Shanghai (HL-085)

          Recruiting
          • Neurofibromatosis 1
          • Plexiform Neurofibromas
          • Shanghai, Shanghai, China
            Shanghai Ninth People's Hospital, Shanghai JiaoTong University S
          Apr 10, 2022

          Neurofibromatosis, MPNST Trial run by the National Cancer Institute (NCI) (MRI, FDG-PET/CT scans, [18F]-FLT-PET/CT scans)

          Completed
          • Neurofibromatosis
          • MPNST
          • MRI, FDG-PET/CT scans
          • [18F]-FLT-PET/CT scans
          • Bethesda, Maryland
            National Institutes of Health Clinical Center, 9000 Rockville Pi
          Aug 24, 2022

          Neurofibromatosis Type 1 Trial in Worldwide (Selumetinib)

          Active, not recruiting
          • Neurofibromatosis Type 1
          • Rochester, Minnesota
          • +8 more
          Nov 10, 2022

          Low-grade Glioma, Plexiform Neurofibroma, CNS Glioma Trial in Canada (Trametinib)

          Active, not recruiting
          • Low-grade Glioma
          • +2 more
          • Calgary, Alberta, Canada
          • +6 more
          Oct 25, 2022

          Neurofibromatosis Type 1, Plexiform Neurofibromas, Post-operative Trial in Beijing, Shanghai (Selumetinib, Placebo)

          Not yet recruiting
          • Neurofibromatosis Type 1
          • +2 more
          • Beijing, China
          • +2 more
          Apr 11, 2023

          (PRO) Measures for Individuals With Neurofibromatosis 1 and

          Recruiting
          • Neurofibromatosis 1
          • Plexiform Neurofibromas
            • Bethesda, Maryland
              National Institutes of Health Clinical Center
            Feb 2, 2023

            Neurofibromatosis Type 1, Plexiform Neurofibroma, Optic Nerve Glioma Trial in London (Selumetinib)

            Recruiting
            • Neurofibromatosis Type 1
            • +2 more
            • London, United Kingdom
            • +1 more
            Nov 11, 2021

            NF type1 With Inoperable Plexiform Neurofibromas Trial in New Orleans (Selumetinib)

            Approved for marketing
            • NF type1 With Inoperable Plexiform Neurofibromas
            • New Orleans, Louisiana
              Research Site
            Apr 30, 2020

            Frameshift Peptides of Children With NF1

            Completed
            • Neurofibromatosis Type 1
            • Frameshift Array blood sample test
            • Washington, District of Columbia
            • +2 more
            Aug 29, 2022

            Neurofibroma, Neurofibroma, Plexiform Trial (Cryotherapy)

            Not yet recruiting
            • Neurofibroma
            • Neurofibroma, Plexiform
            • Cryotherapy
            • (no location specified)
            Jan 19, 2022

            Neurofibromatosis 1, Plexiform Neurofibroma, NF1 Trial in China, Spain, United States (FCN-159)

            Recruiting
            • Neurofibromatosis 1
            • +2 more
            • Los Angeles, California
            • +11 more
            Jul 25, 2022

            Refractory Cancer, CNS Tumors, CNS Tumor, Adult Trial in Atlanta, New York (Avutometinib)

            Recruiting
            • Refractory Cancer
            • +14 more
            • Atlanta, Georgia
            • +1 more
            Oct 23, 2023